T. Rowe Price Associates’s CareDx CDNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.49M | Buy |
52,291
+5,290
| +11% | +$115K | ﹤0.01% | 2140 |
|
|
2026
Q1 | $816K | Buy |
47,001
+7,783
| +20% | +$147K | ﹤0.01% | 2242 |
|
|
2025
Q4 | $739K | Buy |
39,218
+711
| +2% | +$11.9K | ﹤0.01% | 2216 |
|
|
2025
Q3 | $560K | Buy |
38,507
+3,964
| +11% | +$56.5K | ﹤0.01% | 2317 |
|
|
2025
Q2 | $675K | Buy |
34,543
+5,124
| +17% | +$91K | ﹤0.01% | 2158 |
|
|
2025
Q1 | $523K | Buy |
29,419
+2,303
| +8% | +$49.6K | ﹤0.01% | 2240 |
|
|
2024
Q4 | $581K | Buy |
27,116
+3,016
| +13% | +$73.4K | ﹤0.01% | 2226 |
|
|
2024
Q3 | $753K | Sell |
24,100
-6,031
| -20% | -$150K | ﹤0.01% | 2079 |
|
|
2024
Q2 | $468K | Buy |
30,131
+735
| +3% | +$8.88K | ﹤0.01% | 2217 |
|
|
2024
Q1 | $312K | Buy |
29,396
+2,344
| +9% | +$23.4K | ﹤0.01% | 2417 |
|
|
2023
Q4 | $325K | Sell |
27,052
-15,937
| -37% | -$131K | ﹤0.01% | 2347 |
|
|
2023
Q3 | $301K | Buy |
42,989
+6,839
| +19% | +$63.2K | ﹤0.01% | 2334 |
|
|
2023
Q2 | $308K | Buy |
36,150
+4,640
| +15% | +$38.7K | ﹤0.01% | 2352 |
|
|
2023
Q1 | $289K | Sell |
31,510
-236,291
| -88% | -$3.02M | ﹤0.01% | 2361 |
|
|
2022
Q4 | $3.06M | Sell |
267,801
-139,962
| -34% | -$2.07M | ﹤0.01% | 1315 |
|
|
2022
Q3 | $6.94M | Sell |
407,763
-682
| -0.2% | -$14.6K | ﹤0.01% | 1137 |
|
|
2022
Q2 | $8.77M | Sell |
408,445
-323,737
| -44% | -$8.98M | ﹤0.01% | 1341 |
|
|
2022
Q1 | $27.1M | Sell |
732,182
-116,631
| -14% | -$4.55M | ﹤0.01% | 1152 |
|
|
2021
Q4 | $38.6M | Buy |
848,813
+77,404
| +10% | +$4.04M | ﹤0.01% | 1089 |
|
|
2021
Q3 | $48.9M | Sell |
771,409
-8,428
| -1% | -$642K | ﹤0.01% | 1018 |
|
|
2021
Q2 | $71.4M | Sell |
779,837
-22,989
| -3% | -$1.83M | 0.01% | 909 |
|
|
2021
Q1 | $54.7M | Sell |
802,826
-615,515
| -43% | -$47.8M | 0.01% | 971 |
|
|
2020
Q4 | $103M | Buy |
1,418,341
+65,135
| +5% | +$3.77M | 0.01% | 719 |
|
|
2020
Q3 | $51.3M | Sell |
1,353,206
-482,112
| -26% | -$16.3M | 0.01% | 862 |
|
|
2020
Q2 | $65M | Buy |
1,835,318
+1,695,800
| +1,215% | +$48.3M | 0.01% | 763 |
|
|
2020
Q1 | $3.05M | Buy |
+139,518
| New | +$3.13M | ﹤0.01% | 1413 |
|
|
2019
Q4 | – | Sell |
-160,889
| Closed | -$3.64M | – | 2532 |
|
|
2019
Q3 | $3.64M | Sell |
160,889
-305,329
| -65% | -$8.46M | ﹤0.01% | 1427 |
|
|
2019
Q2 | $16.8M | Buy |
466,218
+60,500
| +15% | +$1.94M | ﹤0.01% | 1226 |
|
|
2019
Q1 | $12.8M | Buy |
405,718
+85,030
| +27% | +$2.48M | ﹤0.01% | 1282 |
|
|
2018
Q4 | $8.06M | Buy |
+320,688
| New | +$8.24M | ﹤0.01% | 1339 |
|
|
2015
Q3 | – | Sell |
-16,504
| Closed | -$107K | – | 2517 |
|
|
2015
Q2 | $107K | Sell |
16,504
-11,231
| -40% | -$61K | ﹤0.01% | 2452 |
|
|
2015
Q1 | $154K | Buy |
+27,735
| New | +$183K | ﹤0.01% | 2411 |
|
Other funds holding CDNA
DM
AIM
GS
T. Rowe Price Associates's CDNA Position: Q2 2026 in Review
T. Rowe Price Associates increased its CareDx (CDNA) stake by 11% in Q2 2026, buying an estimated $115K and bringing the position to 52,291 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2140.
T. Rowe Price Associates first reported a position in CDNA in Q1 2015 and has held it in 32 quarters since. The position peaked at $103M in Q4 2020. 228 funds tracked by Wall St. Rank hold CDNA as of Q2 2026.
- T. Rowe Price Associates held 52,291 shares of CareDx worth $1.49M as of Q2 2026.
- T. Rowe Price Associates bought 5,290 CareDx shares in Q2 2026, an estimated $115K.
- CareDx made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2140 holding.
- T. Rowe Price Associates first reported a position in CareDx in Q1 2015 and has held it in 32 quarters since.
- T. Rowe Price Associates's CareDx position peaked at $103M in Q4 2020.
- 228 funds tracked by Wall St. Rank held CareDx as of Q2 2026.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.